She had Covid twice; She also has a blood cancer diagnosis; This serious initial Spontaneous safety report was received by Novavax on 23-Jan-2025 from a Consumer or other non-health professional via Novavax Medical Information (Case No. NOV25-00044). A 72-year-old Female was vaccinated with Novavax COVID-19 Vaccine, Adjuvanted (2024 – 2025 Formula) (Intramuscular) (Lot number was not provided in the report) on an unspecified date. No medical history was reported. No concomitant medications were reported. On an unspecified date after vaccination the patient experienced She also has a blood cancer diagnosis (PT: Haematological malignancy) (Serious: Other Medically Important Condition) and on an unspecified date after vaccination the patient experienced She had Covid twice (PT: COVID-19). At the time of reporting, the event outcome of Haematological malignancy was Unknown and COVID-19 was Unknown.; Sender’s Comments: This 72-year-old Female experienced Haematological malignancy and COVID-19 after vaccination with Novavax COVID-19 Vaccine, Adjuvanted (2024 – 2025 Formula). The event Haematological malignancy was assessed as serious. The event COVID-19 was reported as non-serious. Based on the spontaneous nature of the report, the causal relationship between Novavax COVID-19 Vaccine, Adjuvanted (2024 – 2025 Formula) and Haematological malignancy and COVID-19 is considered Possible.